ELAN’S €2 billion plus asset sell-off may have come to an end yesterday with the disposal of potential Botox competitor Myobloc for up to €15 million.

EUROPEAN markets were mainly in the red yesterday, the Irish index bucked this negative trend and closed 6.25 points higher at 5418.12.

ISEQ-listed Elan Corporation today announced that it has completed the sale of its worldwide rights to Myobloc/Neurobloc injectable solution to Solstice Neurosciences a newly-formed company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products.